* CervoMed Inc is expected to report resultson March 22 (estimated) for the period ending December 31 2023
* The Boston Massachusetts-based company is expected to report revenue of $2 million, according to the estimate from one analyst, based on LSEG data.
* LSEG's mean analyst estimate for CervoMed Inc is for a loss of 29 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for CervoMed Inc is $50.00, above its last closing price of $24.44.
This summary was machine generated March 20 at 20:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments